Читать «Кето-навигатор» онлайн - страница 154

52. Там же.

53. Itomura M, Fujioka S, Hamazaki K, et al. Factors influencing EPA+DHA levels in red blood cells in Japan. In Vivo.2008 Jan-Feb; 22 (1): 131–135.

54. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. 2004 Jul; 39: 212–220.

55. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res. 2007 Jan 15; 73 (2): 310–315.

56. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995 Nov 1; 274 (17): 1363–1367.

57. Zampelas A, Roche H, Knapper JM, et al. Differences in postprandial lipaemic response between Northern and Southern Europeans. Atherosclerosis. 1998 Jul; 139 (1): 83–93.

58. Perez-Jimenez F, Lopez-Miranda J, Mata P. Protective effect of dietary monounsaturated fat on arteriosclerosis: beyond cholesterol. Atherosclerosis. 2002 Aug; 163 (2): 385–398.

59. Dubnov G, Berry EM. Omega-6/omega-3 fatty acid ratio: the Israeli paradox. World Rev Nutr Diet. 2003; 92: 81–91.

60. Yam D, Eliraz A, Berry EM. Diet and disease – the Israeli paradox: possible dangers of a high omega-6 polyunsaturated fatty acid diet. Isr J Med Sci. 1996 Nov; 32 (11): 1134–1143.

61. Renaud S, de Lorgeril M, Delaye J, et al. Cretan Mediterranean diet for prevention of coronary heart disease. Am J Clin Nutr.1995 Jun 1; 61 (6): 1360s–1367s.

62. Covas MI, Nyyssonen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 Sep 5; 145 (5): 333–341.

63. Там же.

64. Is your olive oil fake? [Интернет]. Mercola.com. 2016 Dec 17 [открыто 4 июня 2018]. Доступно по адресу https://articles.mercola.com/sites/articles/archive/2016/12/17/fake-olive-oil.aspx.

Глава шестая

1. Borkman M, Storlien LH, Pan DA, et al. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med. 1993 Jan 28; 328 (4): 238–244.

2. Vessby B, Gustafsson IB, Tengblad S, et al. Desaturation and elongation of Fatty acids and insulin action. Ann N Y Acad Sci.2002 Jun; 967: 183–195.

3. de Lorgeril M, Salen P, Defaye P, et al. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med. 2013; 11: 5.

4. Rise P, Ghezzi S, Priori I, et al. Differential modulation by simvastatin of the metabolic pathways in the n-9, n-6 and n-3 fatty acid series, in human monocytic and hepatocytic cell lines. Biochem Pharmacol. 2005 Apr 1; 69 (7): 1095–1100.

5. de Lorgeril M, Salen P, Guiraud A, et al. Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutr Metab Cardiovasc Dis. 2005 Feb; 15 (1): 36–41.

6. Nozue T, Yamamoto S, Tohyama S, et al. Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention. Am J Cardiol.2013 Jun1; 111 (11): 1570–1575.